Pacemakers to syringes: Why India needs fair pricing for medical devices
Source Entity
The Indian Express
India's medical device sector is facing critical scrutiny due to outdated regulatory frameworks and exploitative pricing. Experts are calling for a dedicated policy to decouple devices from pharmaceutical regulations to ensure patient affordability.
The Crisis of Medical Device Pricing in India
India’s medical device sector has undergone a period of rapid expansion, positioning the nation as a significant player in the global healthcare supply chain. However, this growth has outpaced the regulatory infrastructure intended to oversee it. As noted by industry experts and regulatory officials, the current oversight mechanisms are struggling to keep up with the complexity of modern medical technology, leaving a void that often results in consumer harm.
The Regulatory Mismatch
The core of the current issue lies in the application of the Drugs (Prices Control) Order (DPCO) to medical devices. Historically, the Indian regulatory system has treated medical devices as if they were pharmaceutical drugs, a "pharma-centric" approach that fails to account for the unique lifecycle, manufacturing costs, and distribution channels associated with devices like pacemakers and syringes. This regulatory misalignment has created a environment where pricing mechanisms are fundamentally distorted.
Exploitative Margins and Patient Impact
Maharashtra FDA Commissioner Tukaram Munde recently highlighted the prevalence of exploitative margins within the sector. These inflated Maximum Retail Prices (MRPs) place an undue financial burden on patients, who often face high out-of-pocket costs for essential medical interventions. When the regulatory framework does not distinguish between a simple consumable and a complex life-saving device, it inadvertently allows for price gouging that can prevent patients from accessing necessary care.
The Need for a Distinct Framework
Experts like Rajiv Nath have long advocated for a shift toward a distinct regulatory framework specifically tailored for medical devices. By decoupling devices from the existing pharmaceutical price control structures, India could foster a more competitive market. A specialized regulatory approach would allow for clearer definitions of price caps and trade margins, which would benefit both the patient and the ethical manufacturer who is currently being penalized by the current system.
Broader Implications for the Healthcare Ecosystem
If the current trajectory continues, the lack of transparency in device pricing threatens to undermine the overall trust in the healthcare ecosystem. An environment where ethical manufacturers are sidelined due to an unfair pricing landscape discourages innovation and domestic production. Establishing a dedicated framework is not merely a matter of price control; it is an essential step toward professionalizing the market and ensuring that the rapid growth of the sector translates into improved patient outcomes rather than inflated corporate profits.
Future Trends and Reform
Looking ahead, the pressure for reform is mounting. Policymakers are increasingly recognizing that the status quo is unsustainable. Future trends likely point toward a more data-driven approach to price monitoring and a move away from the blanket application of pharma-based controls. As India seeks to become a global hub for medical technology, aligning its regulatory standards with the realities of the device market will be the defining challenge for the coming decade.